ResApp Health Limited (ASX:RAP) is developing healthcare solutions to assist doctors and empower patients to diagnose and manage respiratory disease on smartphones without the need for additional hardware. ResApp’s core technology uses sound to diagnose respiratory diseases including pneumonia, bronchiolitis, bronchitis, chronic obstructive pulmonary disease and asthma.
Level 12, 100 Creek St
Brisbane, QLD 4000
Board of Directors
Dr Roger Aston – Non-Executive Chairman
Dr Tony Keating – Chief Executive Officer and Managing Director
Chris Ntoumenopoulos – Non-Executive Director
Dr Michael Stein – Non-Executive Director
Australian Securities Exchange
ASX code: RAP
Please refer to the ASX website for current share price and history.
Link Market Services Limited
Level 12 QV1 Building
250 St Georges Terrace
Perth WA 6000
Investor Relations Contact
VP, Corporate Affairs
+61 412 281 780
ResApp Health Limited
ABN 51 094 468 318
Level 12, 100 Creek St, Brisbane, QLD 4000
© 2021 ResApp Health Limited. All rights reserved. US Patent No. 10,098,569, Australian Patent No. 2013239327, Japanese Patent No. 6,435,257, South Korean Patent No. 1020812410000 and Patents Pending. ResApp Health®, the ResApp Health logo and ResAppDx® are registered trademarks of ResApp Health Limited in the United States and other countries. ResAppDx is not available for sale in the United States.